| Literature DB >> 35135811 |
Luigi Ippolito1, Giuseppina Comito1, Elisa Giannoni1, Paola Chiarugi1, Matteo Parri1, Marta Iozzo1, Assia Duatti1, Francesca Virgilio1, Nicla Lorito1, Marina Bacci1, Elisa Pardella1, Giada Sandrini2,3, Francesca Bianchini1, Roberta Damiano1, Lavinia Ferrone4, Giancarlo la Marca1, Sergio Serni5, Pietro Spatafora5, Carlo V Catapano2, Andrea Morandi1.
Abstract
Lactate is an abundant oncometabolite in the tumor environment. In prostate cancer, cancer-associated fibroblasts (CAF) are major contributors of secreted lactate, which can be taken up by cancer cells to sustain mitochondrial metabolism. However, how lactate impacts transcriptional regulation in tumors has yet to be fully elucidated. Here, we describe a mechanism by which CAF-secreted lactate is able to increase the expression of genes involved in lipid metabolism in prostate cancer cells. This regulation enhanced intracellular lipid accumulation in lipid droplets (LD) and provided acetyl moieties for histone acetylation, establishing a regulatory loop between metabolites and epigenetic modification. Inhibition of this loop by targeting the bromodomain and extraterminal protein family of histone acetylation readers suppressed the expression of perilipin 2 (PLIN2), a crucial component of LDs, disrupting lactate-dependent lipid metabolic rewiring. Inhibition of this CAF-induced metabolic-epigenetic regulatory loop in vivo reduced growth and metastasis of prostate cancer cells, demonstrating its translational relevance as a therapeutic target in prostate cancer. Clinically, PLIN2 expression was elevated in tumors with a higher Gleason grade and in castration-resistant prostate cancer compared with primary prostate cancer. Overall, these findings show that lactate has both a metabolic and an epigenetic role in promoting prostate cancer progression. SIGNIFICANCE: This work shows that stromal-derived lactate induces accumulation of lipid droplets, stimulates epigenetic rewiring, and fosters metastatic potential in prostate cancer. ©2022 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35135811 PMCID: PMC7612586 DOI: 10.1158/0008-5472.CAN-21-0914
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 13.312